LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

CureVac NV

Închisă

5.38 -0.19

Rezumat

Modificarea prețului

24h

Curent

Minim

5.33

Maxim

5.4

Indicatori cheie

By Trading Economics

Venit

-409M

-39M

Vânzări

-479M

14M

P/E

Medie Sector

5.864

50.291

EPS

-0.156

Marjă de profit

-266.508

Angajați

825

EBITDA

-410M

-35M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-23.35% downside

Dividende

By Dow Jones

Următoarele câștiguri

14 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

478M

1.2B

Deschiderea anterioară

5.57

Închiderea anterioară

5.38

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

CureVac NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iul. 2024, 09:14 UTC

Achiziții, Fuziuni, Preluări

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

12 iun. 2025, 14:20 UTC

Achiziții, Fuziuni, Preluări

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 iun. 2025, 13:34 UTC

Acțiuni populare

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

3 iul. 2024, 14:18 UTC

Achiziții, Fuziuni, Preluări

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 iul. 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Comparație

Modificare preț

CureVac NV Așteptări

Obiectiv de preț

By TipRanks

-23.35% jos

Prognoză pe 12 luni

Medie 4.17 USD  -23.35%

Maxim 5.5 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCureVac NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

0

Cumpărare

4

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

3.47 / 3.755Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.